title: NICE guidance on omalizumab for severe asthma.
authors.affiliation: National Institute for Health and Care Excellence, London, UK.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Diaz
authors.affiliation: National Institute for Health and Care Excellence, London, UK.
authors.forename: Zoe
authors.initials: Z
authors.lastname: Charles
authors.affiliation: National Institute for Health and Care Excellence, London, UK.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: George
authors.affiliation: National Institute for Health and Care Excellence, London, UK.
authors.forename: Amanda I
authors.initials: AI
authors.lastname: Adler
mesh_terms: D000293:Adolescent; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000191:economics / Q000494:pharmacology; D000888:Antibodies, Anti-Idiotypic / Q000191:economics / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000494:pharmacology; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002648:Child; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D000069444:Omalizumab; D017410:Practice Guidelines as Topic; D012130:Respiratory Hypersensitivity / Q000150:complications*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab